Shanghai Hile Bio-Technology's Subsidiary Secures Indonesian Approval for GORORISE Collagen Membrane

Stock News04-07 16:31

Shanghai Hile Bio-Technology Co.,Ltd. (603718.SH) has announced that its subsidiary, Shaanxi Ruisheng Biotechnology Co., Ltd., received approval from the Indonesian Ministry of Health for its GORORISE Resorbable Collagen Membrane product. The application for registration was submitted in December 2025, and the approval was recently granted.

The GORORISE Resorbable Collagen Membrane is a decellularized extracellular matrix (dECM) material developed and manufactured by Ruisheng Biotechnology. Following tooth loss, the alveolar bone in the affected area often undergoes progressive resorption due to a lack of functional stimulation, which can lead to insufficient bone volume for dental implant procedures.

To address this issue, the resorbable collagen membrane is used in combination with bone graft materials in oral implant surgery. It helps reconstruct alveolar bone tissue in the implant area for patients with missing teeth. When there is a horizontal or vertical bone deficiency in the implant site, the membrane prevents the infiltration of fibroblasts and epithelial cells from soft tissues, thereby creating the necessary time and space for slower-proliferating osteoblasts to enter the bone defect area and promote the regeneration of bone and periodontal tissues.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment